Working groups
Dr. Andy Poumbourios is co-Head of the Viral Entry and Vaccines research group at Burnet Institute and the lead of the SARS-CoV-2 stream of the Burnet Vaccine Initiative. His career has followed an interest in the therapeutic and immunogenic potential of viral envelope proteins that mediate cellular entry.
With a focus on understanding how the Spike proteins of HIV-1, human T cell leukemia virus and hepatitis C virus perform their functions and how this relates to their structures, Andy has applied this knowledge to the development of Burnet hepatitis C vaccine, publishing and patenting its development over the last decade. This knowledge has now facilitated the discovery of the Burnet vaccine candidate for SARS-CoV-2, which in turn brought about the formation of the Burnet Vaccine Initiative.
Andy has won multiple NHMRC grants and holds granted patents.
Journal of Leukocyte Biology
Morgane M. Brunton-O’Sullivan, Olaf G. Wilhelm, Christine Jordan, Hans Kek, Laura Rikard-Bell, Pantelis Poumbourios, Bruce D. Wines, Anthony Jaworowski, Anna C. Hearps, Hans Kek
Journal of Leukocyte Biology
Morgane M. Brunton-O’Sullivan, Olaf G. Wilhelm, Christine Jordan, Hans Kek, Laura Rikard-Bell, Pantelis Poumbourios, Bruce D. Wines, Anthony Jaworowski, Anna C. Hearps, Hans Kek
Journal of Leukocyte Biology
Morgane M. Brunton-O’Sullivan, Olaf G. Wilhelm, Christine Jordan, Hans Kek, Laura Rikard-Bell, Pantelis Poumbourios, Bruce D. Wines, Anthony Jaworowski, Anna C. Hearps, Hans Kek
No hepatitis C vaccine exists due to the virus's genetic diversity, a critical gap in global health. We aim to develop a vaccine that overcomes these hurdles.
A ‘sterilising’ HIV cure requires the elimination of all cellular sources of HIV, including those persisting in long-lived cells. This will require dedicated strategies.
Vaccination is a highly effective strategy to protect populations against infectious diseases. Highly protective and long-lasting vaccines are needed to reduce the global burden of malaria and enable elimination.
HIV-1 continues to have a devasta1ng impact in resource-poor regions where antiretroviral therapy is not widely available.
Rapid high-throughput neutralisation assays are essential for analysis of immune responses in human infection and animal experiments.